How does the 17q21.31 inversion polymorphism mechanistically contribute to severe COVID-19 susceptibility?

OPEN

The study identifies a ~0.9-Mb inversion creating two differentiated haplotypes associated with severe COVID-19, but the functional mechanisms linking this structural variant to disease severity remain unexplained. Understanding this mechanism could reveal new therapeutic targets for severe respiratory failure. Gap type: unexplained_observation Source paper: Detailed stratified GWAS analysis for severe COVID-19 in four European populations. (2022, Human molecular genetics, PMID:35848942)

Priority: 0.80 Domain: immunology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How does the 17q21.31 inversion polymorphism mechanistically contribute to severe COVID-19 susceptibility? is a 0.8 priority gap in immunology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How does the 17q21.31 inversion polymorphism mechanistically contribute to severe COVID-19 susceptibility? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (1)

InosineCOVID-19

biomarker for (1)

InosineCOVID-19

causes (3)

Sars-Cov-2COVID-19COVID-19CoagulopathyCOVID-19Blood-Brain Barrier Disruption

risk factor for (1)

NLRP3COVID-19

shares differentially expressed genes with (1)

36626425COVID-19

upregulated in (2)

P2RX1COVID-19P2RX4COVID-19

upregulates (3)

P2RX1COVID-19P2RX7COVID-19NLRP3COVID-19
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps